Physician profile
Reed A Mathias
NPI 1174563704
$3,792.34
in general payments reported to CMS, 2019-2025
31 companies · $19.61 in 2025
The $19.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $519 · 2021: $908 · 2022: $720 · 2023: $551 · 2024: $52.50 · 2025: $19.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.77 | 2019-2023 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $395.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.56 | 2019-2022 | |
| Amgen INC. | $317.68 | 2019-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.25 | 2019-2023 | Glyxambi, Jardiance, Synjardy |
| Abbvie INC. | $254.32 | 2019-2023 | |
| Dexcom, INC. | $250.16 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $248.44 | 2019-2022 | |
| Astellas Pharma US INC | $181.36 | 2019-2024 | Veozah |
| Acadia Pharmaceuticals INC | $105.40 | 2021 | |
| Abbott Laboratories | $102.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.51 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $86.48 | 2019-2023 | |
| Lilly USA, LLC | $80.15 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $71.30 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $59.83 | 2019-2023 | Shingrix |
| Sunovion Pharmaceuticals INC. | $55.69 | 2019 | |
| Lundbeck LLC | $54.12 | 2023 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $49.48 | 2020-2021 | |
| Exact Sciences Corporation | $27.50 | 2023 | Cologuard Collection Kit |
| Inari Medical, INC. | $25.42 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Esperion Therapeutics, INC. | $24.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.04 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.64 | 2021 | |
| Merck Sharp & Dohme LLC | $14.01 | 2021 | |
| Shield Therapeutics INC | $12.43 | 2022 | |
| Eisai INC. | $12.21 | 2021 | |
| Almatica Pharma LLC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.